{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:12:00Z","timestamp":1789517520064,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T00:00:00Z","timestamp":1241395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    Bilastine is a new non\u2010sedative H\n                    <jats:sub>1<\/jats:sub>\n                    receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To assess and compare the efficacy and safety of bilastine 20\u2003mg vs. cetirizine 10\u2003mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    Overall, 683 SAR patients, aged 12\u201370 years, were randomized to a double\u2010blind treatment with bilastine 20\u2003mg, cetirizine 10\u2003mg or placebo, once daily for 14 days, in 61 centres across Europe. Patients recorded reflective (over the past 12\u2003h) and instantaneous nasal (obstruction, rhinorrhoea, itching and sneezing) and non\u2010nasal (ocular tearing, redness and itching) symptom scores (NSS and NNSS, respectively) twice daily, according to a pre\u2010determined severity scale to provide reflective and instantaneous total symptom scores (TSS). The primary efficacy measure was the area under curve (AUC) of reflective TSS over 14 days of treatment (TSS\u2010AUC\n                    <jats:sub>0\u221214 days<\/jats:sub>\n                    ). Secondary efficacy measures included mean change from baseline in TSS, NSS and NNSS; discomfort caused by AR; and investigator's clinical global impression of the treatment. Safety was assessed according to adverse events (AEs), laboratory tests and electrocardiograms.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    The mean TSS\u2010AUC\n                    <jats:sub>0\u221214 days<\/jats:sub>\n                    (score \u00d7 day) was reduced in bilastine\u2010 and cetirizine\u2010treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001). Similarly, bilastine and cetirizine were comparable and significantly superior to placebo for all secondary outcomes. While all treatments were well tolerated and the AE profiles of bilastine and placebo were similar, significantly fewer patients in the bilastine\u2010treated group experienced somnolence (1.8%;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001) and fatigue (0.4%;\n                    <jats:italic>P<\/jats:italic>\n                    =0.02) than patients in the cetirizine\u2010treated group (7.5% and 4.8%, respectively).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    Bilastine 20\u2003mg once daily was significantly superior to placebo and comparable to cetirizine 10\u2003mg in relieving symptoms of SAR, although it demonstrated a significantly better AE profile than cetirizine.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2222.2009.03257.x","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T05:45:01Z","timestamp":1241415901000},"page":"1338-1347","source":"Crossref","is-referenced-by-count":91,"title":["Efficacy and safety of bilastine 20\u2003mg compared with cetirizine 10\u2003mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double\u2010blind, parallel\u2010group study"],"prefix":"10.1111","volume":"39","author":[{"given":"P.","family":"Kuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nowacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Van Cauwenberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Agache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fouquert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sologuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Valiente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Bilastine International Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00013904"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125003053"},{"key":"e_1_2_6_5_2","unstructured":"Task force on allergic disorders. The allergy report. American Academy of Allergy Asthma and Immunology. Available athttp:\/\/www.aaaai.org\/professionals.stm(accessed July 2008)."},{"key":"e_1_2_6_6_2","first-page":"195","article-title":"Poor sleep and daytime somnolence in allergic rhinitis","volume":"1","author":"Kakumanu S","year":"2002","journal-title":"significance of nasal congestion"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.4.9912033"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62543-4"},{"key":"e_1_2_6_9_2","first-page":"925","article-title":"From allergic rhinitis to sinus diseases (sinusitis\/nasal polyps)","volume":"17","author":"Demoly P","year":"2000","journal-title":"epidemiologic and experimental links"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106150"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62612-9"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70126-X"},{"key":"e_1_2_6_13_2","first-page":"1099","article-title":"A treatment for allergic rhinitis","volume":"21","author":"Holgate S","year":"2005","journal-title":"a view on the role of levocetirizine"},{"key":"e_1_2_6_14_2","first-page":"287","article-title":"The role of histamine in allergic disease","volume":"57","author":"Bachert C.","year":"2002","journal-title":"re-appraisal of its inflammatory potential"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra033121"},{"key":"e_1_2_6_16_2","first-page":"1","article-title":"Current trends in allergic reactions","volume":"5","author":"Gelfand EW","year":"2003","journal-title":"a multidisciplinary approach to patient management"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02159.x"},{"key":"e_1_2_6_18_2","first-page":"1305","article-title":"Consensus group on new\u2010generation antihistamines. Consensus group on new\u2010generation antihistamines (CONGA)","volume":"33","author":"Holgate ST","year":"2003","journal-title":"present status and recommendations"},{"key":"e_1_2_6_19_2","unstructured":"Bilastine (F\u201096221\u2010BMI). A novel antihistamine compound for the treatment of allergic rhinitis and chronic idiopathic urticaria. Available athttp:\/\/www.faes.es(Accessed July 2008)."},{"key":"e_1_2_6_20_2","first-page":"675","article-title":"Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine","volume":"28","author":"Garc\u00eda\u2010Gea C","year":"2008","journal-title":"a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments"},{"issue":"88","key":"e_1_2_6_21_2","first-page":"85","article-title":"Lack of significant effect of bilastine on ventricular repolarization. A thorough QT\/QTc study","volume":"63","author":"Sologuren A","year":"2008","journal-title":"Allergy"},{"key":"e_1_2_6_22_2","first-page":"1198","article-title":"Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine","volume":"47","author":"Sologuren A","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_23_2","first-page":"371","article-title":"Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist","volume":"6","author":"Corcostegui R","year":"2005","journal-title":"receptor selectivity and in vitro antihistaminic activity"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200607040-00002"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01813.x"},{"key":"e_1_2_6_26_2","unstructured":"US Department of Health and Human Services FDA CDER.Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products Draft guidance April 2000."},{"key":"e_1_2_6_27_2","unstructured":"Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. CHMP\/EWP\/2455\/02 EMEA October 2004."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.t01-1-00202.x"},{"key":"e_1_2_6_29_2","first-page":"391","article-title":"Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis","volume":"23","author":"Murray JJ","year":"2002","journal-title":"impact on symptoms, quality of life, productivity, and activity impairment"},{"key":"e_1_2_6_30_2","first-page":"351","article-title":"The health\u2010related quality of life effects of once\u2010daily cetirizine HCl in patients with seasonal allergic rhinitis","volume":"33","author":"Noonan MJ","year":"2003","journal-title":"a randomized double-blind, placebo-controlled trial"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2009.03257.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2009.03257.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:26:04Z","timestamp":1695954364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2009.03257.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,5]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1365-2222.2009.03257.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03257.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,5]]}}}